Exelixis, Inc. - Common Stock (NQ:EXEL)

59.30 +0.91 (+1.55%)

Delayed Quote Updated: 3:42 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Exelixis Announces $550 Million Share Repurchase Program

March 20, 2023

From Exelixis, Inc.

Via Business Wire

3 Beaten-Down Stocks That Could Soar This Year ↗

March 18, 2023

These stocks could enjoy big rebounds in 2023.

Via The Motley Fool

Exelixis Stock Generating Improved Relative Strength Rating ↗

March 16, 2023

Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76.

Via Investor's Business Daily

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

2 Stocks to Buy With Less Than $20 ↗

March 10, 2023

Some relatively low-priced shares can be good buys, too.

Via The Motley Fool

The Latest Analyst Ratings for Exelixis ↗

March 03, 2023

Via Benzinga

Looking Into Exelixis's Return On Capital Employed ↗

February 08, 2023

Via Benzinga

Exelixis (EXEL) Q4 2022 Earnings Call Transcript ↗

February 08, 2023

EXEL earnings call for the period ending December 31, 2022.

Via The Motley Fool

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

March 13, 2023

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the Dip ↗

March 11, 2023

A 33% plunge in the previously high-flying Nasdaq Composite is the perfect time for growth investors to pounce on some amazing deals.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 ↗

March 09, 2023

Via Benzinga

Earnings Outlook For Exelixis ↗

February 06, 2023

Via Benzinga

Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo ↗

March 03, 2023

Via Benzinga

US Stocks Look To Snap String Of Weekly Losses As Futures Signal Positive Start Ahead Of Service Sector Data, Fed Speeches ↗

March 03, 2023

U.S. stocks have returned to their cautious ways after their resilience performance on Thursday. The major index futures point to a modestly higher opening on Friday. Cues From Thursday’s Trading:

Via Benzinga

Dell, Zscaler, Marvell Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 03, 2023

U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

March 02, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 28, 2023

From Exelixis, Inc.

Via Business Wire

Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip ↗

February 18, 2023

A 33% plunge in the growth-dependent Nasdaq Composite is the perfect excuse for investors to buy into these innovative businesses.

Via The Motley Fool

Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer ↗

February 14, 2023

Via Benzinga

2 Under-the-Radar Biotech Stocks to Buy in 2023 ↗

February 14, 2023

These stocks may soon start turning heads with their revenue growth.

Via The Motley Fool

Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

February 13, 2023

From Bristol Myers Squibb and Exelixis, Inc.

Via Business Wire

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

February 13, 2023

From Exelixis, Inc.

Via Business Wire

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

February 12, 2023

These companies could grow in prominence in the coming years.

Via The Motley Fool

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 07, 2023

From Exelixis, Inc.

Via Business Wire

3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗

February 04, 2023

All three healthcare stocks are showing solid long-term potential.

Via The Motley Fool

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

February 02, 2023

From Exelixis, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023 ↗

January 26, 2023

Via Benzinga

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 24, 2023

From Exelixis, Inc.

Via Business Wire

Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue ↗

January 20, 2023

Via Benzinga

Exelixis Announces Update on Patent Litigation with MSN Laboratories

January 19, 2023

From Exelixis, Inc.

Via Business Wire

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.